What will the recent accelerated approval of anti-amyloid lecanemab mean for Alzheimers patients, and will it overcome stringent CMS reimbursement policies?
We take a look at the approval of Relyvrio, the third approved treatment for ALS, and the first to show both a slowing of disease progression and extended survival.
Could the FDA approval of Auvelity usher in a new class of antidepressants? The new oral treatment for depression works with the glutamate receptor NMDA.